Preclinical studies using decoy antisense STAT3 oligonucleotides, dominant-negative vectors, and small-molecule inhibitors have provided convincing evidence that STAT3 is highly relevant to the growth and survival of many tumor types [15-21], in vitro and in vivo. Here, STAT3 is linked to neoplasm.